XFOR stock icon

X4 Pharmaceuticals
XFOR

$0.70
1.39%
 

About: X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 93

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

70% more capital invested

Capital invested by funds: $84.1M [Q4 2023] → $143M (+$59.1M) [Q1 2024]

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

15% more call options, than puts

Call options by funds: $705K | Put options by funds: $611K

7% more funds holding

Funds holding: 91 [Q4 2023] → 97 (+6) [Q1 2024]

1.39% more ownership

Funds ownership: 59.93% [Q4 2023] → 61.33% (+1.39%) [Q1 2024]

8% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 25

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3
327%
upside
Avg. target
$4.50
541%
upside
High target
$5
612%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
612%upside
$5
Buy
Reiterated
28 Jun 2024
Cantor Fitzgerald
Kristen Kluska
612%upside
$5
Overweight
Reiterated
31 May 2024
HC Wainwright & Co.
Swayampakula Ramakanth
612%upside
$5
Buy
Maintained
30 Apr 2024
HC Wainwright & Co.
Swayampakula Ramakanth
327%upside
$3
Buy
Reiterated
22 Mar 2024

Financial journalist opinion

Based on 3 articles about XFOR published over the past 30 days